Advertisement
ViewpointIn-Press Preview Free access | 10.1172/JCI147553
1Department of Molecular Microbiology and Immunology, Johns Hopkins University, Baltimore, United States of America
2Department of Gynecology and Obstetrics, Johns Hopkins University, Baltimore, United States of America
Find articles by Klein, S. in: JCI | PubMed | Google Scholar |
1Department of Molecular Microbiology and Immunology, Johns Hopkins University, Baltimore, United States of America
2Department of Gynecology and Obstetrics, Johns Hopkins University, Baltimore, United States of America
Find articles by Creisher, P. in: JCI | PubMed | Google Scholar |
1Department of Molecular Microbiology and Immunology, Johns Hopkins University, Baltimore, United States of America
2Department of Gynecology and Obstetrics, Johns Hopkins University, Baltimore, United States of America
Find articles by Burd, I. in: JCI | PubMed | Google Scholar |
Published January 14, 2021 - More info
Limited evidence exists regarding the use of the currently approved COVID-19 mRNA vaccines (Pfizer-BioNtech BNT162b2 and Moderna mRNA-1273) during pregnancy. In this Viewpoint, Klein et al. discuss gaps in knowledge and make recommendations to incorporate age, sex, and pregnancy in the preclinical and clincal vaccine development pipeline.